-
Something wrong with this record ?
Pyelovesicostomy as an Alternative Surgical Treatment for Complex Ureteral Lesions After Kidney Transplant
P. Navratil, S. Sahi, J. Spacek, J. Pacovsky, M. Lesko, I. Gunka, D. Astapenko
Language English Country Turkey
Document type Observational Study, Journal Article
NLK
Free Medical Journals
from 2003
Freely Accessible Science Journals
from 2003
Medline Complete (EBSCOhost)
from 2011-12-01
ROAD: Directory of Open Access Scholarly Resources
from 2003
PubMed
37885285
DOI
10.6002/ect.2023.0204
Knihovny.cz E-resources
- MeSH
- Adult MeSH
- Cohort Studies MeSH
- Humans MeSH
- Retrospective Studies MeSH
- Aged MeSH
- Kidney Transplantation * adverse effects methods MeSH
- Ureter * surgery pathology MeSH
- Treatment Outcome MeSH
- Check Tag
- Adult MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Observational Study MeSH
OBJECTIVES: We evaluated the feasibility, safety, and long-term outcomes of pyelovesicostomy as an alternative surgical treatment for complex ureteral lesions after kidney transplant. MATERIALS AND METHODS: A single-center, retrospective, observational cohort study was conducted on 5 adult kidney transplant recipients who underwent pyelovesicostomy between January 2000 and June 2023. The collected data included patient demographics, surgery indication, time from transplant to pyelovesicostomy, procedure details, and kidney function at various time points after surgery. Primary outcomes were allograft function and complications. RESULTS: The 5 patients (4 female, 1 male) had a mean age of 65.8 years and mean body mass index of 26.8. Indications were complex ureteral lesions. The time between transplant and reoperation ranged from 4 days to 12 years. Renal function improved for all patients, with a progressive decrease in mean serum creatinine concentration. The mean follow-up period extended to 7 years. One patient died with the graft still functional at 20 years after the operation, whereas the remaining 4 patients continue to live with functional grafts. CONCLUSIONS: Our study suggests that pyelovesicostomy may provide a potent alternative for the management of complex ureteral lesions after kidney transplant. We have observed good short-term and long-term outcomes in specific patients, pointing toward a promising avenue oftreatment worth further exploration. This reaffirms the importance of a personalized approach in medicine, to consider each patient's unique conditions and characteristics during therapeutic decisions.
From the Department of Urology University Hospital Hradec Kralove Czech Republic
the Charles University Faculty of Medicine Hradec Kralove Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24001248
- 003
- CZ-PrNML
- 005
- 20240213094454.0
- 007
- ta
- 008
- 240109s2023 tu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.6002/ect.2023.0204 $2 doi
- 035 __
- $a (PubMed)37885285
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a tu
- 100 1_
- $a Navratil, Pavel $u From the Department of Urology, University Hospital Hradec Kralove, Czech Republic; the Charles University, Faculty of Medicine, Hradec Kralove, Czech Republic
- 245 10
- $a Pyelovesicostomy as an Alternative Surgical Treatment for Complex Ureteral Lesions After Kidney Transplant / $c P. Navratil, S. Sahi, J. Spacek, J. Pacovsky, M. Lesko, I. Gunka, D. Astapenko
- 520 9_
- $a OBJECTIVES: We evaluated the feasibility, safety, and long-term outcomes of pyelovesicostomy as an alternative surgical treatment for complex ureteral lesions after kidney transplant. MATERIALS AND METHODS: A single-center, retrospective, observational cohort study was conducted on 5 adult kidney transplant recipients who underwent pyelovesicostomy between January 2000 and June 2023. The collected data included patient demographics, surgery indication, time from transplant to pyelovesicostomy, procedure details, and kidney function at various time points after surgery. Primary outcomes were allograft function and complications. RESULTS: The 5 patients (4 female, 1 male) had a mean age of 65.8 years and mean body mass index of 26.8. Indications were complex ureteral lesions. The time between transplant and reoperation ranged from 4 days to 12 years. Renal function improved for all patients, with a progressive decrease in mean serum creatinine concentration. The mean follow-up period extended to 7 years. One patient died with the graft still functional at 20 years after the operation, whereas the remaining 4 patients continue to live with functional grafts. CONCLUSIONS: Our study suggests that pyelovesicostomy may provide a potent alternative for the management of complex ureteral lesions after kidney transplant. We have observed good short-term and long-term outcomes in specific patients, pointing toward a promising avenue oftreatment worth further exploration. This reaffirms the importance of a personalized approach in medicine, to consider each patient's unique conditions and characteristics during therapeutic decisions.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a senioři $7 D000368
- 650 12
- $a transplantace ledvin $x škodlivé účinky $x metody $7 D016030
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 12
- $a ureter $x chirurgie $x patologie $7 D014513
- 650 _2
- $a kohortové studie $7 D015331
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a pozorovací studie $7 D064888
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Sahi, Sukhdeep
- 700 1_
- $a Spacek, Jiri
- 700 1_
- $a Pacovsky, Jaroslav
- 700 1_
- $a Lesko, Michal
- 700 1_
- $a Gunka, Igor
- 700 1_
- $a Astapenko, David
- 773 0_
- $w MED00174388 $t Experimental and clinical transplantation $x 2146-8427 $g Roč. 21, č. 9 (2023), s. 712-716
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37885285 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240109 $b ABA008
- 991 __
- $a 20240213094451 $b ABA008
- 999 __
- $a ok $b bmc $g 2049704 $s 1210942
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 21 $c 9 $d 712-716 $e - $i 2146-8427 $m Experimental and clinical transplantation $n Exp Clin Transplant $x MED00174388
- LZP __
- $a Pubmed-20240109